High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Patients With Cirrhosis: Data From the Turquoise-II Study

被引：0
|
作者：
Pol, Stanislas
Andreone, Pietro
Lee, Samuel
Bourliere, Marc
Bourgeois, Stefan
Tang, Yuanyuan
Trinh, Roger
Martinez-Tristani, Marisol
Pockros, Paul J.
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1019
引用
收藏
页码：S1086 / S1086
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders
    Sonsuz, Abdullah
    Bozcan, Selma
    Hatemi, Ibrahim
    Ozdemir, Sebati
    Canbakan, Billur
    Yildirim, Suleyman
    Gulturk, Ilkay
    Ar, Cem
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (05): : 414 - 420
  • [42] Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir±Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice
    Belperio, Pamela S.
    Bhattacharya, Debika
    Shahoumian, Troy A.
    Loomis, Timothy P.
    Goetz, Matthew B.
    Mole, Larry A.
    Backus, Lisa I.
    HEPATOLOGY, 2016, 64 : 957A - 958A
  • [43] EFFICACY AND SAFETY OF PARITAPREVIR/RITONAVIR, OMBITASVIR AND DASABUVIR PLUS/ MINUS RIBAVIRIN FOR TREATMENT OF HCV GENOTYPE 1B COMPENSATED CIRRHOSIS IN PATIENTS AGED 70 YEARS OR OLDER
    Trifan, Anca
    Prelipcean, Cristina Cijevschi
    Gheorghe, Liana
    Curescu, Manuela
    Brisc, Ciprian
    Bataga, Simona
    Miftode, Egidia
    Arama, Victoria
    Rogoveanu, Ion
    Suceveanu, Andra Iulia
    Singeap, Ana Maria
    Chiriac, Stefan A.
    Cuciureanu, Tudor
    Sporea, Ioan
    Goldis, Adrian
    Popescu, Alina
    Iacob, Speranta
    Sfarti, Catalin
    Cojocariu, Camelia
    Stefanescu, Gabriela
    Girleanu, Irina
    Stoica, Oana
    Mihai, Catalina
    Ciortescu, Irina
    Stanciu, Carol
    GASTROENTEROLOGY, 2017, 152 (05) : S904 - S904
  • [44] A low incidence of hepatocellular carcinoma in patients with genotype 1b compensated cirrhosis treated with paritaprevir/ritonavir, ombitasvir and dasabuvir ± ribavirin in a tertiary center: a matter of better selection?
    Chiriac, S.
    Trifan, A.
    Stanciu, C.
    Prelipcean, C. C.
    Stefanescu, G.
    Mihai, C.
    Sfarti, C.
    Cojocariu, C.
    Cuciureanu, T.
    Mihai, F.
    Singeap, A. M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S630 - S630
  • [45] GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis
    Poordad, Fred
    Sedghi, Shahriar
    Pockros, Paul J.
    Ravendhran, Natarajan
    Reindollar, Robert
    Lucey, Michael R.
    Epstein, Michael S.
    Bank, Leslie
    Bernstein, David E.
    Trinh, Roger
    Krishnan, Preethi
    Pilot-Matias, Tami
    Polepally, Akshanth R.
    Pothacamury, Rajvineeth K.
    Unnebrink, Kristina
    Martinez, Marisol
    Nelson, David R.
    HEPATOLOGY, 2016, 64 : 431A - 432A
  • [46] A LOW INCIDENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH GENOTYPE 1B COMPENSATED CIRRHOSIS TREATED WITH PARITAPREVIR/RITONAVIR, OMBITASVIR AND DASABUVIR A± RIBAVIRIN IN A TERTIARY CENTER: A MATTER OF BETTER SELECTION?
    Chiriac, Stefan A.
    Trifan, Anca
    Stanciu, Carol
    Prelipcean, Cristina Cijevschi
    Stefanescu, Gabriela
    Mihai, Catalina
    Sfarti, Catalin
    Cojocariu, Camelia
    Cuciureanu, Tudor
    Mihai, Florin
    Singeap, Ana Maria
    GASTROENTEROLOGY, 2017, 152 (05) : S903 - S903
  • [47] Comparative Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir±Ribavirin in 6,961 Genotype 1 Patients Treated in Routine Medical Practice
    Backus, Lisa I.
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Loomis, Timothy
    Mole, Larry
    GASTROENTEROLOGY, 2016, 150 (04) : S1036 - S1036
  • [48] PREDICTORS OF HEPATIC DECOMPENSATION DURING OMBITASVIR/PARITAPREVIR/RITONAVIR ± DASABUVIR ± RIBAVIRIN TREATMENT OF GENOTYPE 1 AND 4 HCV INFECTED PATIENTS (REAL LIFE AMBER STUDY)
    Flisiak, R.
    Jaroszewicz, J.
    Janczewska, E.
    Wawrzynowicz-Syczewska, M.
    Grabinska, A.
    Bolewska, B.
    Pisula, A.
    Karpinska, E.
    Mozer-Lisewska, I.
    Madej, G.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S815 - S815
  • [49] Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study
    Flisiak, Robert
    Janczewska, Ewa
    Wawrzynowicz-Syczewska, Marta
    Jaroszewicz, Jerzy
    Zarebska-Michaluk, Dorota
    Nazzal, Khalil
    Bolewska, Beata G.
    Bialkowska, Jolanta
    Berak, Hanna
    Fleischer-Stepniewska, Katarzyna M.
    Tomasiewicz, Krzysztof
    Karwowska, Kornelia
    Rostkowska, Karolina
    Piekarska, Anna
    Tronina, Olga
    Madej, Grzegorz
    Garlicki, Aleksander
    Lucejko, Mariusz
    Pisula, Arkadiusz
    Karpinska, Ewa A.
    Kryczka, Wieslaw
    Wiercinska-Drapalo, Alicia
    Mozer-Lisewska, Iwona
    Jablkowski, Maciej S.
    Horban, Andrzej
    Knysz, Brygida
    Tudrujek, Magdalena
    Halota, Waldemar
    Simon, Krzysztof.
    HEPATOLOGY, 2016, 64 : 987A - 987A
  • [50] 100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients
    Sanai, F. M.
    Alghamdi, A. S.
    Afghani, A.
    Alswat, K. A.
    Aseeri, A.
    Babatin, M. A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S312 - S312
12345